BioDuro, a trusted global contract research, development, and manufacturing organisation, has announced a groundbreaking partnership with Silicogenix, the pioneer of fit-for-purpose small molecule design technology that empowers polypharmacology and non-traditional drug development. The collaboration combines BioDuro’s leading drug discovery platform with SGX’s novel frameworks to lower the cost and time barriers in developing complex therapies.
SGX’s technology enables biopharma companies to rapidly initiate and test new therapies, including possible combinations with standard-of-care treatments, due to their ability to access the majority of the human proteome. Leveraging the leading drug discovery platform, BioDuro delivers various complex molecules at speed, and accelerating the path from drug discovery through to preclinical at a lower cost.
